Jove
Visualize
Contact Us

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the OPA1 pathway in Autosomal Dominant Optic Atrophy (ADOA): 25 years from gene discovery to therapeutic strategy.

Expert opinion on therapeutic targets·2026
Same author

Targeted OMA1 therapies for cancer.

International journal of cancer·2019
Same author

Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis.

Science translational medicine·2017
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.3K

OMA1 High-Throughput Screen Reveals Protease Activation by Kinase Inhibitors.

Marcel V Alavi1

  • 1712 North Inc., QB3 Incubator at UC Berkeley, 130 Stanley Hall, #3220, Berkeley, California 94720, United States.

ACS Chemical Biology
|October 21, 2021
PubMed
Summary

Researchers developed a new assay to screen for drugs targeting the mitochondrial protease OMA1, crucial for diseases like heart failure and cancer. This assay can identify both OMA1 activators and inhibitors, paving the way for new therapeutic strategies.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 3, 2026

Identification of Kinase-substrate Pairs Using High Throughput Screening
11:13

Identification of Kinase-substrate Pairs Using High Throughput Screening

Published on: August 29, 2015

8.3K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Mitochondrial proteases, like OMA1, are challenging drug targets for multifactorial diseases.
  • OMA1 plays a role in energy metabolism and stress signaling by cleaving OPA1 and DELE1.
  • Limited knowledge exists regarding OMA1's structure, regulation, and inhibition.

Purpose of the Study:

  • To develop a scalable, cellular assay for high-throughput drug screening of OMA1 activity.
  • To identify potential activators and inhibitors of OMA1 for therapeutic development.
  • To investigate potential cross-reactivity of existing drugs with the OMA1 pathway.

Main Methods:

  • Engineered a luciferase reporter targeted to the inner mitochondrial membrane as an artificial OMA1 substrate.
  • Developed a cellular assay where reporter signal inversely correlates with OMA1 activity.
  • Validated the assay using different screening protocols and compound collections.

Main Results:

  • Successfully established and validated a scalable OMA1 protease assay for drug screening.
  • Demonstrated the assay's capability to identify both OMA1 activators and inhibitors.
  • Identified ten kinase-targeted cancer drugs that triggered OMA1 activity, suggesting potential cross-reactivity.

Conclusions:

  • The developed assay is suitable for high-throughput screening of OMA1 modulators.
  • OMA1 is a promising drug target for heart failure, neurodegeneration, and cancer.
  • Kinase-targeted cancer drugs may interact with the OMA1 pathway, potentially explaining cardiotoxicity.